Related Experiment Videos
Use of intravenous hydrocortisone in Henoch-Schonlein purpura
Journal of Paediatrics and Child Health
|July 27, 2001
Insights
Henoch-Schonlein purpura (HSP) is a potential cause of severe abdominal pain in children. Early corticosteroid treatment may resolve symptoms and prevent invasive procedures.
Area of Science:
- Pediatric Gastroenterology
- Pediatric Nephrology
- Pediatric Rheumatology
Background:
- Henoch-Schonlein purpura (HSP) is the most common vasculitis affecting children.
- Abdominal pain is a frequent and often severe symptom of HSP.
Observation:
- Children presenting with severe abdominal pain unresponsive to standard treatments warrant consideration for HSP.
- Diagnostic workup may not reveal an apparent cause for the abdominal pain.
Findings:
- A trial of intravenous corticosteroids can lead to dramatic symptom improvement in children with HSP.
- Prompt corticosteroid administration may obviate the need for further investigations and surgical intervention.
Implications:
- Early recognition and treatment of HSP can significantly improve patient outcomes.
- Corticosteroid therapy offers a non-invasive approach to managing HSP-related abdominal pain.
- This approach can reduce healthcare costs associated with extensive diagnostic workups and surgeries.
Abstract:
Henoch-Schonlein purpura should be considered in children with severe abdominal pain that is unresponsive to conventional treatment when no apparent cause is found on investigation. Such children may respond dramatically to a trial of intravenous corticosteroid and, hence, may avoid unnecessary investigations and laparotomy.